Vitality Watch

Dossier clinicaltrials trial early 21-jul-2026
Small or early-phase human trial or pilot study

Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide

Key claim: A multi-disciplinary exercise-plus-nutrition intervention is being tested against standard advice to slow declines in muscle mass, strength, and physical function in adults 65+ with type 2 diabetes and obesity on weekly semaglutide.

Abstract

This study aims to test whether a multi-disciplinary intervention involving exercise and nutrition can slow down the decline in physical function, muscle strength and mass in older adults (aged 65 and above) with Type 2 diabetes (T2D) and obesity treated with Semaglutide.

The main questions it aims to answer are:

In older people with T2D and obesity, treated with Semaglutide, does a multi-disciplinary intervention of exercise and nutrition compared to standard health recommendations:

  1. Reduce the rate of decline in muscle mass?
  2. Reduce the rate of decline in muscle strength?
  3. Reduce the rate of decline in physical function?

Participants will:

Administer Semaglutide once weekly for 6 months. Visit the clinic once every 8 weeks for checkups and tests. Keep a diary of their food consumption. Participants in the intervention group will participate in an online exercise program and will receive personal nutritional counseling.

Why this matters

As GLP-1 prescribing expands into older adults, sarcopenia risk from rapid weight loss has become the dominant safety concern shadowing the AOM-as-geroprotector narrative. This trial joins a small but growing set of registered adjunct protocols (protein/HMB, resistance training, structured nutrition) attempting to convert that concern into a testable mitigation strategy — but as of now it is a design, not a result, and the muscle-preservation claims circulating in trend media still outrun the evidence base.

Source

Link

Briefing card

Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide
Stage: trial early · clinicaltrials · 21-jul-2026

A multi-disciplinary exercise-plus-nutrition intervention is being tested against standard advice to slow declines in muscle mass, strength, and physical function in adults 65+ with type 2 diabetes and obesity on weekly semaglutide.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT06497595

build build 880 · 2bcef25 · 2026-11-18